title: Resveratrol prolongs allograft survival after liver transplantation in rats.
abstract: OBJECTIVE
  To study the immuno-modulatory effect of resveratrol (RES) on allograft rejection after liver transplantation in rats.
  
  
  METHODS
  Male Sprague-Dawley (SD) rats were selected as donors and male Wistar rats as recipients for a rejection model. The recipients were divided into four groups after orthotopic liver transplantation (OLTx). In the RES A, B, and C groups, RES was given intra-peritoneally once a day (25, 50, and 100 mg/kg, respectively) after OLTx, whereas in the control group, vehicle buffer was given intra-peritoneally once a day. The survival time, serum chemistry, production of cytokines, activation of transcription factor NF-kappaB, and histopathologic findings were then compared among these groups.
  
  
  RESULTS
  The mean survival time after OLTx in the RES C group was significantly longer than that in the control group (16.7+/-1.2 d vs 9.3+/-0.6 d, P<0.01). On the 7th post-transplant day the serum albumin level significantly improved in the RES C group, the serum total bile acid and alanine aminotransferase (ALT) levels were significantly lower in the RES C group, the serum IL-2 and INF-gamma levels were significantly lower in the RES C group, and the activation of transcription factor NF-kappaB in peripheral blood T lymphocytes was significantly suppressed in the RES A, B, and C groups in comparison to those in the control group. On the 7th post-transplant day, a histological examination revealed apparent difference in the severity of rejection between the RES C group and control group.
  
  
  CONCLUSIONS
  RES has an immuno-suppressive property as well as protective effect on hepatocytes under allograft rejection. It might serve as a novel agent for reducing the severity of hepatic allograft rejection in rats.
authors.affiliation: Department of Hepatobiliary Surgery, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. victorywu2000@163.com
authors.forename: Sheng-Li
authors.initials: SL
authors.lastname: Wu
authors.forename: Liang
authors.initials: L
authors.lastname: Yu
authors.forename: Ke-Wei
authors.initials: KW
authors.lastname: Meng
authors.forename: Zhen-Hua
authors.initials: ZH
authors.lastname: Ma
authors.forename: Cheng-En
authors.initials: CE
authors.lastname: Pan
mesh_terms: D000818:Animals; D006085:Graft Survival / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016328:NF-kappa B; D013267:Stilbenes; D000077185:Resveratrol